# NCT03575611 (NCT03575611)

> Stereotactic Body Radiation Therapy in Treating Patients With Oligometastatic Renal Cell Carcinoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03575611
- Phase: PHASE2
- Status: SUSPENDED
- Sponsor: M.D. Anderson Cancer Center
- Conditions: Metastatic Renal Cell Carcinoma; Stage IV Renal Cell Cancer AJCC v8
- Interventions: Biopsy; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Positron Emission Tomography; Stereotactic Body Radiation Therapy
- Enrollment: 123
- Primary outcome: Feasibility of incorporating definitive radiation therapy (RT) (such as stereotactic body radiation therapy [SBRT]) into treatment plan for oligometastatic renal cell carcinoma (RCC) in lieu of systemic therapy
- Primary outcome: Feasibility of incorporating definitive RT (such as SBRT) as a treatment strategy for low metastatic burden RCC in lieu of systemic therapy
- Primary outcome: Progression-free survival (PFS) in oligometastatic RCC per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
- Primary outcome: PFS in low metastatic burden RCC per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03575611